Evidence map›Paper›PMID 35643492›Full record

ArticleAIDS research and therapy2022

Comparison of predictors for early and late mortality in adults commencing HIV antiretroviral therapy in Zimbabwe: a retrospective cohort study.

Bradley W Byers, Douglas Drak, Tinei Shamu, Cleophas Chimbetete, Rumbi Dahwa, David M Gracey

Abstract read
In one paragraph

Article in AIDS research and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bradley W Byers *Central Clinical School, Faculty of Medicine, The University of Sydney, Sydney, NSW, Australia.
Douglas Drak *Central Clinical School, Faculty of Medicine, The University of Sydney, Sydney, NSW, Australia. ddra8845@uni.sydney.edu.au.
Tinei ShamuNewlands Clinic, Newlands, Harare, Zimbabwe.
Cleophas ChimbeteteNewlands Clinic, Newlands, Harare, Zimbabwe.
Rumbi DahwaFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
David M GraceyCentral Clinical School, Faculty of Medicine, The University of Sydney, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeople living with HIV (PLWHIV) commencing antiretroviral therapy (ART) in sub-Saharan Africa experience significant mortality within the first year. Previously, identified risk factors for mortality may be biased towards these patients, as compared to those who experience late mortality.

aimTo compare risk factors for early and late mortality in PLWHIV commencing ART.

methodsA retrospective cohort study of ART-naïve patients aged ≥ 18 years from an outpatient HIV clinic in Zimbabwe. Data were collected between January 2010 and January 2019. Predictors for early (≤ 1 year) and late mortality (> 1 year) were determined by multivariable cox proportional hazards analyses, with patients censored at 1 year and landmark analysis after 1 year, respectively.

resultsThree thousand and thirty-nine PLWHIV were included in the analysis. Over a median follow-up of 4.6 years (IQR 2.5-6.9), there was a mortality rate of 8.8%, with 50.4% of deaths occurring within 1 year. Predictors of early mortality included CD4 count < 50 cells/µL (HR 1.84, 95% CI 1.24-2.72, p < 0.01), WHO Stage III (HR 2.05, 95% CI 1.28-3.27, p < 0.01) or IV (HR 2.83, 95% CI 1.67-4.81, p < 0.01), and eGFR < 90 mL/min/1.73 m

conclusionsTraditional markers of mortality risk in patients commencing ART appear to be limited to early mortality. Proteinuria and diabetes are some of the few predictors of late mortality, and should be incorporated into routine screening of patients commencing ART.

Indexed as

Anti-HIV AgentsHIV InfectionsAdultAnti-Retroviral AgentsHumansProteinuriaRetrospective StudiesZimbabweAnti-HIV AgentsAnti-Retroviral AgentsAnti-retroviral therapyCD4 countHIVMortalitySub-Saharan AfricaZimbabwe

Identifiers

PMID35643492
PMCPMC9148446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.